MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1
- Authors:
- Published online on: November 17, 2017 https://doi.org/10.3892/etm.2017.5529
- Pages: 1672-1679
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
Abstract
microRNA (miR) are a class of endogenous small non‑coding RNA that are aberrantly expressed and are critical in tumorigenesis. Amongst them, miR‑152 was reported to be dysregulated in epithelial ovarian cancer (EOC). However, the function and mechanism of miR‑152 is not well understood. In the present study, total RNA was extracted from 58 ovarian epithelial carcinoma tissue samples and adjacent non‑tumor tissues and measured by reverse transcription‑quantitative polymerase chain reaction. The observations of the present study revealed that the expression of miR‑152 was significantly downregulated in EOC specimens, as well as three ovarian cancer (OC) cell lines. The higher expression of miR‑152 indicated a better overall survival rate in patients with EOC. Following miR‑152 mimic transfection into SKOV3 or OVCAR3 cells, MTT assay revealed that cell proliferation was significantly inhibited (P<0.05). Although miR‑152 had no effect on SKOV3 cell migration, miR‑152 inhibited OVCAR3 cell migration. Bioinformatics analyses and luciferase reporter assays demonstrated that miR‑152 targeted the 3'‑untranslated region (3'-UTR) of the forkhead box protein 1 (FOXP1). Furthermore, introducing FOXP1 without the 3'‑UTR abrogated the effect of miR‑152‑induced proliferation and migration alteration, respectively. In addition, the expression level of FOXP1 was higher in the EOC tumor tissues and cell lines. Additionally, the level of miR‑152 and FOXP1 was inversely correlated in grade 3 and 4 ovarian tumor tissues. Altogether, these observations indicated that miR‑152 may be involved in the inhibition of OC through repression of FOXP1. In the future, miR‑152 and FOXP1 may act as novel biomarkers for early detection of EOC or therapeutic targets.